NASDAQ:PAVM PAVmed Q2 2026 Earnings Report $5.72 -0.22 (-3.63%) Closing price 03:58 PM EasternExtended Trading$5.72 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PAVmed EPS ResultsActual EPSN/AConsensus EPS -$0.63Beat/MissN/AOne Year Ago EPSN/APAVmed Revenue ResultsActual RevenueN/AExpected Revenue$0.05 millionBeat/MissN/AYoY Revenue GrowthN/APAVmed Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile PAVmed Earnings HeadlinesPAVmed Shareholders Approve Plan Changes at Annual MeetingJune 24, 2026 | tipranks.comHow The PAVmed (PAVM) Narrative Is Shifting With Reworked Assumptions And A Lower Price TargetJune 1, 2026 | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 20 at 1:00 AM | Profits Run (Ad)PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ...May 15, 2026 | finance.yahoo.comPAVmed Inc.: PAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | finanznachrichten.dePAVmed (PAVM) Q4 2025 Earnings TranscriptMay 15, 2026 | finance.yahoo.comSee More PAVmed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PAVmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PAVmed and other key companies, straight to your email. Email Address About PAVmedPAVmed (NASDAQ:PAVM) is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology. Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions. The company completed its initial public offering in 2017 and maintains research, development and regulatory operations in North America and strategic partnerships in Europe. PAVmed’s multidisciplinary team leverages clinical insights, engineering expertise and regulatory know-how to shepherd devices from concept through pivotal studies and commercialization. PAVmed’s executive leadership brings together seasoned professionals from the medical device, clinical practice and regulatory sectors. The management team emphasizes streamlined regulatory pathways and robust clinical trial design, seeking to deliver less-invasive treatment options that address high unmet needs. Though based in the United States, the company’s regulatory clearances and distribution agreements extend into key international markets. Looking ahead, PAVmed is focused on driving commercial adoption of its approved devices while advancing its mid- and late-stage programs toward pivotal data readouts and regulatory submissions. By targeting areas where minimally invasive approaches can improve patient outcomes and reduce healthcare costs, the company aims to establish sustainable growth through a diversified pipeline of differentiated medical technologies.View PAVmed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
